Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised,...

26

Transcript of Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised,...

Page 1: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 2: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 3: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 4: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 5: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 6: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 7: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 8: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 9: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 10: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 11: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 12: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 13: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 14: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 15: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 16: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 17: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 18: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 19: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 20: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 21: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 22: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 23: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 24: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 25: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Page 26: Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis

Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis

Compromised CD4 +  CD25 high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and

Compromised CD4 +  CD25 high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and

Migrants' Remitting beyond Altruism and Self-Interest

Migrants' Remitting beyond Altruism and Self-Interest

How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis

Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis

Design and Synthesis of a Novel Dendrosome and a PEGylated PAMAM Dendrimer Nanocarrier to Improve the Anticancer effect of Turmeric (Curcuma longa) Curcumin

Design and Synthesis of a Novel Dendrosome and a PEGylated PAMAM Dendrimer Nanocarrier to Improve the Anticancer effect of Turmeric (Curcuma longa) Curcumin

Synthesis and Characterization of Well-Defined PEGylated ...

Synthesis and Characterization of Well-Defined PEGylated ...

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

Synthesis and characterization of PEGylated derivatives of rosin for sustained drug delivery

Synthesis and characterization of PEGylated derivatives of rosin for sustained drug delivery

On the interaction of fluorophore-encapsulating PEGylated lecithin liposomes with hamster and human platelets

On the interaction of fluorophore-encapsulating PEGylated lecithin liposomes with hamster and human platelets

Synthesis of PEGylated lactose analogs for inhibition studies on T.cruzi trans-sialidase

Synthesis of PEGylated lactose analogs for inhibition studies on T.cruzi trans-sialidase

Caudate nuclei volume, diffusion tensor metrics, and T 2 relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: Implications for understanding gray matter

Caudate nuclei volume, diffusion tensor metrics, and T 2 relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: Implications for understanding gray matter

Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation

Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation

Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy

Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy

PEGylated chitosan / doxorubicin nanoparticles and ... - CORE

PEGylated chitosan / doxorubicin nanoparticles and ... - CORE

The role of IL-28, IFN-γ, and TNF-α in predicting response to pegylated interferon/ribavirin in chronic HCV patients

The role of IL-28, IFN-γ, and TNF-α in predicting response to pegylated interferon/ribavirin in chronic HCV patients

PEGylated galactosylated cationic liposomes for hepatocytic gene delivery

PEGylated galactosylated cationic liposomes for hepatocytic gene delivery

PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a

PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a

Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis

Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis